UPDATE: One of our holdings blasted through our target today and is still on the rise. So should we sell?
Continue Reading
BUY: This financial publisher's research and opinion is well-suited for the individual investor that wants to beat Wall Street at its own game.
Continue Reading
SELL: On the heels of my recommendation and unrelated speculation the stock rocketed over 200%.
Continue Reading
BUY: Momentum and a short squeeze could drive these mortgage stocks to a double after Labor Day.
Continue Reading
BUY: This company is a prime takeover candidate with a breakthrough treatment for chronic heart failure. Meanwhile our last biotech trade has risen 40% since my recommendation.
Continue Reading
SELL: It's time to let our solar stock go.
BUY: Meanwhile, a pioneer in diabetes treatment may be a takeover candidate, and second-quarter earnings indicate a new growth cycle will restore this trucker's former glory.
Continue Reading
| DJIA |
10,318.16 |
-14.28 |
-0.14 % |
| NASDAQ |
2,146.04 |
-10.78 |
-0.50 % |
| S&P |
1,091.38 |
-3.52 |
-0.32 % |